Understanding the mechanisms of outcome according to the time frame can help optimize the therapeutic development in severe alcoholic hepatitis. We assessed short-term and long-term survival in severe alcoholic hepatitis based on baseline disease severity, extent of therapeutic improvement, long-term influence of alcohol relapse, and their interaction. Data and alcohol consumption were prospectively recorded in 398 patients treated with corticosteroids in the short term (from corticosteroid initiation to 6 months) and long term (from 6 months to maximum follow-up time). Cumulative incidence rate of first alcohol relapse was 25.2%, 33.7%, and 35.2% at 1, 3, and 5 years, respectively. Alcohol relapse (30 g/day) was not associated with mortality (P 5 0.24) during the short-term period (1,606 patient-months at risk), but the Lille (P < 0.0001) and Model for End-Stage Liver Disease (P < 0.0001) scores were independent prognostic factors. In patients who were alive at 6 months (median follow-up, 42 months; interquartile range 11-88), corresponding to 10,413 patient-months at risk, alcohol consumption (30 g/day) was associated with mortality (hazard ratio, 3.9; P < 0.0001). Additional analysis with abstinent patients as a reference showed a dose effect of alcohol on the hazard ratio of death: 2.36 (P 5 0.052) for 1-29 g/day, 3.2 (P 5 0.003) for 30-49 g/day, 3.51 (P < 0.0001) for 50-99 g/day, and 5.61 (P < 0.0001) for 100 g/day. The baseline Model for End-Stage Liver Disease score was not predictive of long-term outcome, while Lille score (P 5 0.02) and alcohol relapse (P < 0.0001) were independent prognostic factors. Conclusion: This study shows that new therapeutic development for severe alcoholic hepatitis must target liver injury in the short term and alcohol consumption in the long term; thus, health agencies can endorse future study designs adapted to the time frame of factors influencing mortality; with this in mind, drug-targeting mechanisms involved in liver injury should only be tested for the short-term period. (HEPATOLOGY 2017;66:1464-1473 
A lcoholic hepatitis (AH), which is an acuteon-chronic liver failure, is associated with possible reversal from decompensated to compensated alcoholic liver disease in a short period of time. (1) (2) (3) (4) This reversal is associated with rapid improvement in the acute process, which involves several key pathways of alcohol-induced liver injury such as inflammation, necrosis, oxidative stress, and regeneration. (2, 3) When it occurs, this rapid improvement in liver function is a strong predictor of short-term outcome and can be assessed by dynamic scores such as the Lille model. (5) Liver failure is frequently reversed in complete responders to medical therapy as defined by the Lille model, while liver function improves less in partial responders and nonresponders do not get any benefit from medical treatment. (6) Thus, survival decreases significantly in the three response-to-therapy groups. (6) In addition, the severity of disease at admission is a strong predictor of short-term outcome. (7) (8) (9) (10) (11) (12) Over the past decade, knowledge of the main contributors to the acute process has improved thanks to cumulative data, and the therapeutic strategy for the short-term outcome has been updated. (13) On the other hand, the therapeutic strategy for the long-term outcome is still a subject of debate. The only established evidence is that persistent alcohol intake results in progression of liver disease from a normal liver to cirrhosis and aggravates the outcome in patients with alcoholic liver disease. (13) (14) (15) (16) (17) (18) Conversely, as pointed out by a systematic review, data evaluating the interaction between progression of liver injury and the effects of alcohol are lacking. (19) When these data become available, clinicians can target the thresholds for short-term improvement that would prevent the risk of long-term liver-related events in abstinent patients. On the other hand, the time course of events in patients with alcohol relapse in relation to their recovery from acute alcohol insult needs to be defined. The long-term death rates may be lower if acute alcohol-related injury is improved by effective management and if alcohol consumption is stopped. On the other hand, certain patients who are abstinent may still die because their liver disease has not sufficiently improved. However, the death rates of these patient groups have never been prospectively evaluated. An understanding of the disease over time could be an important step in helping clinicians to develop a therapeutic strategy that integrates the main factors that may differ for the short-term and long-term outcomes.
The aim of this prospective study was to assess long-term survival in patients with severe AH treated with corticosteroids based on disease severity at baseline, extent of improvement following the acute insult, the long-term influence of alcohol relapse, and their interaction.
Patients and Methods

INCLUSION CRITERIA AND CORTICOSTEROID PROTOCOL
All patients with severe AH admitted in the liver unit of the University Hospital in Lille, France, from January 2002 to September 2015 were prospectively treated with corticosteroids and followed up after corticosteroid treatment had been completed; a systematic follow-up agenda was applied at 2 months, 3 months, 6 months, 9 months, 12 months, and every 6 months thereafter. Inclusion criteria were as follows:
(1) a history of excess alcohol consumption; (2) liver chemistry suggesting AH; (3) transjugular liver biopsy, which was carried out in all patients. The histological diagnosis of AH was based on the presence of hepatocellular necrosis and infiltration of polymorphonuclear leukocytes. (20) We excluded patients with uncontrolled gastrointestinal hemorrhage, neoplasms, a positive test for the hepatitis B surface antigen, and positive PCR for hepatitis C virus and human immunodeficiency virus antibodies. The severity of AH was defined by Maddrey's discriminant function 32.
(11) Systematic screening for infection was performed in all patients at admission, including chest X-ray, ascites fluid examination, blood culture, and urine culture. (21) Screening was repeated in case of suspected infection during follow-up. Once infection had been ruled out or treated, corticosteroids were initiated with a planned 28-day treatment period. Response to treatment was assessed after 7 days by the Lille score. Since 2007, a cutoff for corticosteroids has been proposed in nonresponders defined by the Lille score. (5, 6) The following clinical and biological variables were recorded at admission, and biological data were prospectively obtained during the treatment period (7, 14, 21, 28 prothrombin time, international normalized ratio, albumin, aspartate aminotransferase, creatinine, white blood cell count, polymorphonuclear count, and discriminant function. Clinical and biological parameters were recorded at each visit, and alcohol consumption (in grams per day) was determined from the patient's medical interview. If there was a discrepancy between the patient's self-reported consumption and the physician's belief, blood ethanol was determined. When patients were lost to follow-up or did not attend one or several visits, survival and alcohol relapse data were collected based on family and general practitioner interviews. Patients met with an addiction specialist during their hospital stay if their clinical condition allowed it. Brief motivational interventions were routinely performed, but no alcohol pharmacotherapy was proposed because none of these molecules is approved in decompensated cirrhosis in France. After discharge, evaluation with an addiction specialist was systematically proposed if the patient relapsed.
STATISTICAL ANALYSIS
Quantitative variables are expressed as means (standard deviation) in case of normal distribution or medians (interquartile range [IQR] ). Qualitative variables are expressed as frequencies and percentages. Cumulative incidence and independent predictors of first alcohol relapse (defined as consumption 30 g/ day) after corticosteroid initiation were assessed by treating all-cause death as a competing risk. The Prentice and Kalbfleisch approach (22) was used to estimate the cumulative incidence of a first alcohol relapse, and a backward stepwise Fine-Gray model was used to investigate the independent predictors of a first alcohol relapse. Candidate predictors were age, gender, smoking, living, and socioeconomic conditions (living alone, unemployment, and absence of children). Subhazard ratios (SHRs) were derived from Fine-Gray models (23) as effect size measures with their 95% confidence intervals (CIs); the proportional subhazards assumption was assessed by examining the Schoenfeld residuals. All patients were followed up prospectively, and data from lost to follow-up patients were censored at the final follow-up visit. Certain patients who did not respond to medical treatment underwent liver transplantation based on a careful selection process. (6) Liver transplantation was also offered to certain patients who had stopped drinking alcohol for a certain length of time according to the classical selection process for transplantation in alcoholic cirrhosis. Data were censored at liver transplantation for transplanted patients.
To assess overall survival in patients with severe AH treated by corticosteroids according to pretreatment severity (assessed by the Model for End-Stage Liver Disease [MELD] score), response to therapy (assessed by the Lille model), and alcohol relapse (assessed during follow-up visits after 2 months of treatment), follow-up was divided into two periods in relation to the high risk of death in the 6 months after corticosteroid treatment was begun.
(5) Thus, the short-term period was defined as the beginning of corticosteroids to 6 months and the long-term period as 6 months after corticosteroids (landmark time point) to the maximum available follow-up time. Sensitivity analyses were also reported using 3 months and 1 year as landmark time points to define short-term and long-term periods.
Univariable and multivariable Cox regression models were used to assess the association of mortality from all causes for each time period with the MELD score, the Lille score (treated as continuous variables as well as a binary variable according to the established nonresponder cutoff of 0.45), and alcohol relapse (defined as consumption 30 g/day). Alcohol relapse was treated as a time-dependent covariate in the Cox regression models using all posttreatment alcohol consumption measurements. This model accounted for changes in alcohol relapse over time: for each death, the current alcohol consumption values of the subject who died were compared to the current alcohol consumption values of all other at-risk patients (alive and not lost to follow-up) at the time of death. (24) We checked the log-linearity assumption for the MELD and Lille scores (treated as continuous) using Martingale residual plots and the proportional hazards assumption using the Schoenfeld residual plot. (25) We derived the hazard ratios (HRs) from the Cox regression models as effect size measures with their 95% CIs. For the long-term period, interaction between Lille score (treated as continuous) and alcohol relapse was tested by introducing a multiplicative term into the Cox regression model. To illustrate the possible interaction, a four-level time-dependent variable was created to combine the response to therapy and alcohol relapse in order to estimate the HR for alcohol relapse in responders and nonresponders.
The primary analyses were performed using two categories of alcohol consumption (<0 versus 30 g/ day). Additional analyses were performed for the longterm period only using five categories of alcohol consumption: 0 g/day (used as the reference), 1-29 g/day, 30-49 g/day, 50-99 g/day, and 100 g/day.
Statistical tests were performed using a two-tailed a level of 0.05. Data were analyzed using the SAS software package, release 9.3 (SAS Institute, Cary, NC).
Results
From January 2002 to September 2015, 464 patients with severe AH were admitted to the liver unit. Sixtysix of these patients were excluded from the present study for the following reasons: 32 patients died before beginning corticosteroids (mainly from infection [20 cases]), 12 patients died within 7 days after beginning corticosteroids, and information was missing in 22 patients, making it impossible to calculate the Lille score. The baseline characteristics of the 398 included patients are reported in Table 1 . According to the 0.45 cutoff of the Lille model, 238 (59.8%) patients were responders (i.e., those with a Lille score <0.45) and 160 (40.2%) were nonresponders (i.e., those with a Lille score 0.45). During the study period, 24 patients were early transplanted for severe AH that did not respond to medical treatment. After a period of sobriety, 5 patients were transplanted for persistent liver insufficiency a median of 344 days after inclusion.
The median long-term follow-up period after beginning corticosteroids was 42 months (IQR 11-88 months). In most cases the first alcohol relapse occurred within 3 years of follow-up, with estimated cumulative incidence rates (95% CIs) of 25.2% (20.8-29 .7) at 1 year, 33.7% (28.7-38.7) at 3 years, and 35.2% (30.1-40.3) at 5 years (Fig. 1) . During the follow-up period, 126 patients resumed alcohol consumption 30/g day. The number of patients with an alcohol consumption measurement at each follow-up visit is reported in Table 2 . On backward stepwise multivariable analysis, the independent predictors of first alcohol relapse were younger age (SHR per 10-year decrease, 1.38; 95% CI 1.14-1.66; P 5 0.0007) and living alone (SHR, 1.45; 95% CI 1.01-2.09; P 5 0.047), while gender, tobacco status, parental status, employment status, and past diagnosis of cirrhosis were not. This multivariate analysis was based on 110 alcohol relapses in the 349 patients with no missing data for potential predictors.
SHORT-TERM OUTCOME AND ALCOHOL RELAPSE AFTER CORTICOSTEROID INITIATION
During the 6-month period after beginning corticosteroid therapy 148 patients died (110 within 2 months FIG. 1. Cumulative incidence rates of first alcohol relapse in patients with severe AH treated by corticosteroids. On backward stepwise multivariable analysis, the independent predictors of first alcohol relapse were younger age (SHR per 10-year decrease, 1.38; 95% CI, 1.14-1.66; P 5 0.0007) and living alone (SHR, 1.45; 95% CI 1.01-2.09; P 5 0.047), while gender, tobacco status, parental status, employment status, and past diagnosis of cirrhosis were not. and 126 within 3 months) and a total of 1,606 patientmonths were compiled. One hundred and forty eight short-term deaths occurred from liver insufficiency (37.8%), hepatorenal syndrome (21.6%), gastrointestinal bleeding (12.2%), infection (mostly related to liver insufficiency, 17.6%), cardiovascular events (2.7%), other causes (2%), and unknown causes (6.1%). Thus, mortality was related to liver insufficiency in 89.2% of the cases. Alcohol consumption measurements were available for 90.2% (n 5 239) of 265 patients who were followed up at 2 months and 91.1% (n 5 225) of 247 patients followed up at 3 months (Table 2 ). Based on these 464 alcohol consumption measurements, 10% of follow-up time (corresponding to 161 patient-months) was considered to be the time spent by patients with alcohol consumption 30 g/day (Table 3) . Alcohol consumption 30 g/day was not significantly associated with increased mortality (HR, 1.56; 95% CI 0.74-3.30; P 5 0.24). As expected, the Lille model and MELD score were good predictors of 6-month mortality after corticosteroid therapy began, with a loglinear association; in multivariate analysis, a 0.1 increase in the Lille score was associated with an HR of 1.35 (95% CI 1.27-1.43), and a 5-point increase in the MELD score was associated with an HR of 1.29 (95% CI 1.12-1.48) ( Table 3) . In abstinent patients, improvement was greater in responders than nonresponders over the 6-month period for bilirubin, 
LONG-TERM OUTCOME AND ALCOHOL RELAPSE AFTER CORTICOSTEROID INITIATION
The study population of landmark analysis at 6 months included 218 patients (118 men; 54%, mean age 47.8 years). From the landmark time point to the maximum available follow-up (12 years; median [IQR] follow-up time from landmark, 62 months), 99 patients died and a total of 10,413 patient-months were compiled. Ninety-nine long-term deaths occurred from liver insufficiency (30.3%), hepatorenal syndrome (2%), gastrointestinal bleeding (17.2%), infection (mostly related to liver insufficiency, 17.2%), cancer including hepatocellular carcinoma (10.1%), cardiovascular event (5%), and unknown causes (18.2%). Thus, mortality was related to liver insufficiency in 66.7% of the cases. During this period, a total of 1,581 alcohol consumption measurements were available, and 25% of the follow-up time (corresponding to 2,554 patientmonths) was considered to be time spent by patients with alcohol consumption 30 g/day. Nine patients had a relapse of severe AH. Unlike the short-term period, alcohol consumption 30 g/day was significantly associated with an increased risk of death compared to consumption <30 g/day (HR, 3.90; 95% CI 2.61-5.82). Interestingly, the MELD score at baseline was no longer associated with the long-term risk of death. On the other hand, the Lille score still predicted long-term outcome; however, the prognostic value was lower than for the short-term outcome. A 0.1 increase in the Lille score was associated with an HR of death of 1.11 (95% CI 1.02-1.21). The impact of alcohol consumption 30 g/day on the risk of mortality was not modified by the Lille score (P for interaction 5 0.90). The HR (95%CI) for alcohol consumption 30 g/day was 4.12 (2.62-6.49) in responders and 3.88 (1.63-9.26) in nonresponders. In multivariate analysis, both alcohol consumption 30 g/ day and the Lille score independently predicted longterm mortality, with a multivariate HR of 4.14 (95% CI 2.76-6.20, P < 0.0001) for alcohol consumption 30 g/ day and 1.14 (95% CI 1.05-1.23, P 5 0.002) for each 0.1 increase in Lille model (Table 4 ).
An additional analysis taking no alcohol consumption (0 g/day) as a reference showed a dose effect of alcohol consumption on the risk of mortality, with an HR of 2.36 (95% CI 0.99-5.60) for 1-29 g/day, 3.20 (95% CI 1.48-6.90) for 30-49 g/day, 3.51 (95% CI 2.03-6.06) for 50-99 g/day, and 5.61 (95% CI 3.41-9.23) for greater consumption. In multivariate analysis including the Lille score, this dose-dependent relationship was not modified (Fig. 2) and the Lille score remained associated with mortality (HR per 0.1 increase in Lille model, HR, 1.13; 95% CI 1.04-1.23).
To better define the optimal period of time, we performed additional analyses using 3 months and 1 year as landmark points (Supporting Tables S1-S3 ). This supplementary analysis shows the independent longterm effect of alcohol relapse and Lille score. For the landmark at 3 months, we were not able to perform an analysis during the first 3 months due to a very low number of patients with alcohol relapse, and only analysis for the long-term outcome was performed (Supporting Table S1 ). For the landmark at 1 year, alcohol relapse was shown to influence outcome within the first 12 months (Supporting Table S2 ) and thereafter (Supporting Table S3 ).
Discussion
The present prospective study shows the main factors affecting outcome in severe AH by providing a sequential assessment of clinical and biological parameters associated with the systematic evaluation of patients' alcohol consumption (Fig. 3) . Although the medical interview is a very sensitive method to report alcohol use, (26) alcohol consumption may have been underreported in our study because the blood alcohol level was only obtained in selected cases and other methods, such as the urine ethylglucuronide test, were not applied. The short-term outcome is mainly related to the severity of liver injury at baseline and early improvement in hepatic function. The present study showed that approximately 50% of living nonresponders who were abstinent at 6 months had a MELD score that was still above 17, the traditional cutoff for liver transplantation. (27) These results suggest that the probability of being alive without an indication for liver transplantation in abstinent nonresponders is only around 15% because of the 70% mortality in these patients at 6 months. (5, 10, 28) Conversely, long-term outcome is mainly influenced by alcohol consumption, but this must be analyzed in relation to early improvement in liver injury. This progress in the understanding of the mechanisms of outcome according to the time frame can help optimize the scientific conditions for the development of a therapeutic strategy in severe AH. Thus, time points to test the efficacy of a strategy in relation to the supposed mechanism of action can be more accurately defined for experts and health agencies.
AH is an acute process that occurs in a chronic liver disease. Data on this topic have been misinterpreted because drugs with a short-term effect have been evaluated for their long-term effect, while no long-term strategy has been proposed. Like in other chronic diseases outside the liver, this should be avoided in the future. In a randomized controlled trial on arterial hypertension, (29) the beneficial effect of tight control of blood pressure was confirmed but was shown to disappear during the long term when no strategy to maintain such control was made. Thus, in AH, study designs evaluating a therapeutic strategy that targets the acute insult should only focus on the short-term impact. In addition, during the short-term period, alcohol relapse will have a minor influence on the analysis because this parameter does not significantly affect short-term mortality. To better define the optimal period of time to evaluate drug treatment in AH, we performed supplementary analyses at 3 months and 1 year. This analysis clearly suggests that studies testing molecules should avoid using survival at 1 year as the primary endpoint because data could be strongly influenced by alcohol relapse. Conversely, both the 3-month and the 6-month periods seem to be relevant. Although the 3-month period could be proposed because alcohol relapse begins after 2-3 months, this decision cannot only be based on the present study and should be proposed by a consensus of experts and health agencies.
Conversely, the major impact of alcohol intake on the long-term outcome has been clearly demonstrated in this prospective study, which explores the time frame of this process. The optimal goal of long-term management after an episode of severe AH should be to obtain complete abstinence. Indeed, compared to abstinent patients, the risk of mortality increases even in patients with a daily dose of alcohol <30 g/day, while this threshold is considered to be safe in patients without liver disease because it is not associated with a measurable risk of developing cirrhosis. (30, 31) Another important issue is the proportional relationship between HR and alcohol intake, questioning the relevance of reducing alcohol intake in patients who cannot be completely abstinent. Although this study clearly shows the correlation between alcohol intake and the risk of mortality, it does not confirm that a decrease in alcohol consumption will reduce mortality in patients with severe AH. Nevertheless, reducing alcohol intake in patients who resume alcohol consumption should be mandatory, emphasizing the importance of a multidisciplinary approach that should be begun rapidly after discharge because the first alcohol relapse mainly occurs within the first 3 years.
The present study helps physicians interpret the complex relationship between early improvement in liver injury and subsequent long-term alcohol consumption. At first glance, the therapeutic benefit attained in early responders did not seem to be maintained because of the decrease in survival over the time. The long-term loss of the benefit of corticosteroids has been also observed in a recent randomized controlled trial. (32) However, the design of this randomized controlled trial, like others, was not adapted to evaluate the factors influencing long-term mortality. We have shown the independent prognostic value of alcohol intake and early response to treatment that are predictive of long-term survival with an additive effect. For example, in completely abstinent patients, responders to corticosteroids still have a better long-term outcome than nonresponders. Conversely, any recurrent alcohol consumption influences outcome whatever the type of response to medical therapy, and an additive effect is observed between these two factors. Therefore, scientific societies and experts should be very cautious when interpreting long-term data in studies evaluating shortterm exposure to therapy in relation to the risk of recurrent alcohol consumption over time.
Conversely, improvement in long-term survival following treatment targeting liver injury in severe AH must include secondary prevention to decrease the risk of alcohol relapse or the worsening of liver function. Like in other acute conditions such as stroke or acute cardiovascular events, secondary prevention is the most powerful strategy to reduce the risk of death after an acute episode. For example, stopping smoking reduces the risk of death (33, 34) and stent thrombosis in patients with coronary artery disease, (33) while those who continue to smoke have a greater risk of death and thrombosis. (33) Thus, long-term management should focus on maintaining abstinence or reducing alcohol intake. Although the present study did not address this issue, an alternative therapeutic strategy could involve developing molecules that can prevent the recurrence of the necro-inflammatory process in patients who are not abstinent from alcohol.
In conclusion, this study shows that the therapeutic strategy for severe AH must target liver injury for the short term and alcohol consumption for the long term. Health agencies can identify endpoints in future trials that are adapted to the time frame of the factors influencing mortality. With this in mind, drugs targeting mechanisms involved in liver injury should be tested for the short-term period that switch the patient from decompensated to compensated status alone. However, after recovery from liver injury, new strategies must be evaluated to decrease long-term relapse to heavy drinking or alcohol intake.
